NeuroSense (NRSN) reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer’s disease. The safety analysis indicated a favorable tolerability profile for PrimeC. No serious adverse events were reported, and no new or unexpected safety signals were identified. As an exploratory proof-of-concept study, clinical outcome measures are descriptive by design. NeuroSense will analyze clinical observations alongside biomarker data to enable a more comprehensive interpretation of the clinical observations, with results expected in the first quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Completes Data Collection for Alzheimer’s Trial
- NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug
- NeuroSense Gains FDA Approval for Phase 3 ALS Trial
- NeuroSense reports FDA clearance to initiate Phase 3 trial for PrimeC in ALS
- NRSN Earnings this Week: How Will it Perform?